Karyopharm Therapeutics | KPTI - Ordinary Share Capital


Karyopharm Therapeutics reported $18.31M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Abbott USD 1.74B 23.39B Sep/2025
Amgen USD 540M 1000K Mar/2026
AstraZeneca USD 1.55B 73K Mar/2026
BioCryst Pharmaceuticals USD 213.06M 2.54M Dec/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
GlaxoSmithKline GBP 4.05B 20.6M Mar/2026
Incyte USD 199.95M 1.49M Mar/2026
J&J USD 2.41B 1.74M Dec/2025
Karyopharm Therapeutics USD 18.31M 18.3M Dec/2025
MacroGenics USD 63.56M 241K Mar/2026
Merck USD 2.47B 12.72M Dec/2025
Nektar Therapeutics USD 20.38M 20.36M Dec/2025
Novartis USD 1.91B 60K Mar/2026
Novartis USD 1.91B 60K Mar/2026
Pfizer USD 5.7B 13M Mar/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 795.62M 699.54K Dec/2025
Takeda JPY 1.58B 241K Mar/2026
Tectonic Therapeutic USD 18.83M 92.19K Mar/2026
TG Therapeutics USD 155.31M 95K Dec/2025
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Xencor USD 74.06M 2.19M Mar/2026